胰高血糖素样肽1受体激动剂治疗糖尿病肾病的临床研究进展

糖尿病影响全球健康问题，糖尿病肾病是其通常的微血管并发症之一，而且还是导致肾病的主要疾病之一（ESRD）。目前降血糖药物中的胰高血糖素-1受体激动剂（glucagon-like peptide 1 receptor agonist，GLP-1RA），成为治疗糖尿病患者的主要方法，能有效降低血糖。越来越多的研究表明，无论低血糖效应如何，GLP-1RA都有保护肾脏的作用。本文通过分析临床资料，分析GLP-1RA应用于治疗糖尿病的临床研究进展。

Clinical progress of glucagon-like peptide 1 receptor agonist in treatment of diabetic nephropathy

Diabetes affects global health problems. Diabetes nephropathy is one of its common microvascular complications, and also one of the major diseases leading to nephropathy (ESRD). At present, glucagon-like peptide 1 receptor agonist (GLP-1RA), one of the hypoglycemic drugs, has become the main treatment for diabetes patients, and can effectively reduce blood glucose. More and more studies have shown that GLP-1RA can protect the kidney no matter what the hypoglycemic effect is. This article analyzes the clinical research progress of GLP-1RA in the treatment of diabetes by analyzing clinical data.